देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
HYDROCHLOROTHIAZIDE; CANDESARTAN CILEXETIL
ALEMBIC PHARMACEUTICALS LIMITED
C09DA06
CANDERSARTAN AND DIURETICS
25MG; 32MG
TABLET
HYDROCHLOROTHIAZIDE 25MG; CANDESARTAN CILEXETIL 32MG
ORAL
100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0244181003; AHFS:
APPROVED
2014-06-11
______________________________________________________________________________ _Candesartan Cilexetil and Hydrochlorothiazide Tablets Product Monograph Page 1 of 50_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS candesartan cilexetil and hydrochlorothiazide tablets Tablets, 16 mg / 12.5 mg, 32 mg / 12.5 mg and 32 mg / 25 mg, Oral use House Standard Angiotensin II AT 1 Receptor Blocker + Diuretic CANADIAN IMPORTER AND DISTRIBUTOR: Alembic Pharmaceuticals Canada Ltd. 225 Gibraltar Road, Unit 5 Vaughan, Ontario L4H 4P9, Canada MANUFACTURED BY: Alembic Pharmaceuticals Limited Alembic Road, Vadodara 390003, Gujarat, India. Date of Initial Authorization: June 11, 2014 Submission Control Number: 259876 Date of Revision: July 22, 2022 ______________________________________________________________________________ _Candesartan Cilexetil and Hydrochlorothiazide Tablets Product Monograph Page 2 of 50_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions – Ophthalmologic 07/2022 7 Warnings and Precautions – Carcinogenesis and Mutagenesis 07/2022 7 Warnings and Precautions – Skin 07/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED RECENT MAJOR LABEL CHANGES ……………………………………………..……....2 TABLE OF CONTENTS……………………………………………………………..……....2 PART I: HEALTH PROFESSIONAL INFORMATION ………………… . ………… .. ….. 4 1 INDICATIONS………………………………… . …… . ….……………………..……....4 1.1 Pediatrics….…………………………………..….………………………………..4 1.2 Geriatrics….……………………………………...………………………………..4 2 CONTRAINDICATIONS …………………………………………………………..…4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................. पूरा दस्तावेज़ पढ़ें